6 provinces form a Chinese patent medicine centralized procurement alliance, and the large-scale Chinese patent medicine alliance procurement registration begins

On March 17, the Guangdong Provincial Drug Trading Center issued the "Notice on Viewing Information about Guangdong Alliance Qingkailing and other Chinese patent medicines for centralized procurement of registered products"

The members of Guangdong Traditional Chinese Medicine Centralized Procurement Alliance include Guangdong, Shanxi, Henan, Hainan, Ningxia, and Qinghai provinces

The original text is as follows:

All relevant units:

According to the relevant requirements and work arrangements of the "Guangdong Alliance Qingkailing and Other Chinese Patent Medicines Procurement Documents (GDYJYPDL202103)" (hereinafter referred to as "Procurement Documents"), the centralized procurement of Chinese patent medicines such as Guangdong Alliance Qingkailing is now in line with the application conditions.

1.

(1) Information on the products that meet the application conditions, the price of the products to be declared, and the average daily consumption: see Annex 1;

(2) A/B purchase order list of the amount reported by public medical institutions in the alliance area: see Annex 2;

(3) Registering product price information that meets the application conditions: Please use the CA certificate to log in to the provincial platform trading system, and pass the "Information Publicity/Review Management-Price Publicity Project-Drug Price Publicity-Guangdong Alliance Qingkailing and other proprietary Chinese medicines to collect the volume.

2.

From now until 17:00 on March 21, 2022

3.

(1) If you have any objection to viewing the information, please use the CA certificate to log in to the drug trading system within the specified time, fill in the feedback content through "Information Review/Feedback Management-Other Information Review/Feedback (Drugs)", and follow the requirements Upload the drug information review feedback form (see Annex 3 for the template) and related certification materials, and the feedback materials must be stamped with the official seal of the company page by page; if the feedback materials are not submitted within the specified time, it will be regarded as no objection, and the corresponding consequences will be borne by the company

(2) The content of the objection feedback materials submitted by the enterprise should be true, valid, clear and complete, targeted and unambiguous, and legal and valid evidence materials (including but not limited to certification documents stamped with the official seal of the provincial drug procurement department, winning bids) should be provided in accordance with laws and regulations.

4.

(1) The lowest price is the lowest price of each province (including Guangdong, Shanxi, Jiangxi, Henan, Guangxi, Hainan, Guizhou, Qinghai, Ningxia, Xinjiang and Xinjiang Production and Construction Corps) as of December 1, 2021 (inclusive).

(2) If there is a difference ratio relationship between different dosage forms and specifications of the same product in the same company: take the product with the lowest average daily cost/minimum price difference ratio and the product with the lowest daily cost/price as the price applied product rule, and other applied product specifications The minimum daily average cost/minimum price of the product should be in line with the difference between the minimum daily average cost/minimum price of the price declaration

(3) If there is no difference ratio relationship between the same variety and different dosage forms of the same company: according to the same variety serial number and different groups, take the product with the lowest average daily cost/minimum price difference in the same group of registered product specifications after the ratio of the daily average cost/price.

(4) The lowest price with volume is the lowest selected price collected up to now for the national provincial-level procurement with volume

(5) Relevant enterprises are requested to carefully check and check the price information of their related products.

(6) If there is a situation listed in the "Procurement Documents" of "in the same category and the same competitive unit declaration enterprises, the person in charge of the enterprise is the same person or there is a direct controlling or management relationship", the relevant enterprises are required to make the declaration truthfully within the specified time, and the content of the declaration It needs to include the name of the specific competitive unit involved, the specific relationship with the competitive unit enterprise (the person in charge of the enterprise is the same person/there is a direct controlling relationship/there is a management relationship) and relevant certification materials.
For specific requirements and reporting methods, see the above "Feedback Methods and Requirements"
.
If the declaration is not made within the specified time, it shall be deemed that the enterprise undertakes that the above-mentioned situations do not exist
.

(7) According to the grouping principle of "Purchasing Documents", the Shengmai granules of ginseng prescription/red ginseng prescription and "Appendix 1 "132 Drug Purchase List and Unified Representative Products" - variety serial number 11 Shengmai/Yiqi Fumai-2 Combination preparation (including oral liquid)" should be in the same bidding group, the dosage form of this group in Attached Table 1 is adjusted to "granules/mixture (including oral liquid)", and the drug name is adjusted to "ginseng prescription/red ginseng prescription: raw Maiyin, Shengmaiyin (ginseng recipes), Shengmai granules”; in Schedule 2, “Maximum Average Daily Expenses of 132 Drugs/Highest Valid Quoted Price”, “Ginseng recipes/Red ginseng recipes: Shengmai granules” were added simultaneously.
The highest average daily cost is: 5.
31 yuan/day [granules (sugar-containing type)], 5.
841 yuan/day [granules (sugar-free type)]
.

(8) In Schedule 2 of the "Procurement Documents", the highest average daily cost of "Bucai Oil Emulsion Injection" with variety No.
22 is adjusted to: 113.
98 yuan per day
.

(9) For the benchmark product that has not registered and has not provided specific information (including the certification materials of the provincial drug administration department), the minimum price must be included in the calculation of the difference ratio
.
The ratio of the minimum daily average cost/minimum price of the price declaration rule to the lowest average daily cost of the benchmark rule/minimum price and the difference between the minimum daily cost/minimum price of the other registration rule and the lowest daily average price of the price rule The fee/minimum price should match the difference ratio
.

(10) The enterprise shall be responsible for the authenticity, validity and legitimacy of the submitted feedback materials, and all consequences arising from errors and omissions in the submitted materials shall be borne by the enterprise itself
.

(11) Enterprises must truthfully declare relevant price information and shareholding (management) relationship.
For enterprises that falsely report, omit, conceal or submit false materials, once verified, they will be dealt with in accordance with the relevant provisions of the "Procurement Documents" and corresponding responsibilities It is borne by the enterprise itself
.

5.
Contact information

(1) Online customer service on the official website of Guangdong Drug Trading Center
.

(2) Consultation telephone: 020-38036183, 020-38036197 (working days: 8:30-12:00 14:00-17:30)
.

Attachment: 1.
Registration product information form that meets the application conditions

2.
A/B purchase order list of public medical institutions in the alliance area

3.
Drug Information Review Feedback Form (Template)

Guangdong Drug Trading Center

March 17, 2022